Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - albendazole - tablets - albendazole 400 mg - albendazole - albendazole - albendazole is indicated for the treatment of the following systemic helminth diseases: * echinococcosis (hydatid disease)albendazole is indicated for the treatment of liver, lung and peritoneal cysts. experience with bone cysts and those in the central nervous system and heart is limited. * cystic echinococcosis (caused by echinococcus granulosus)albendazole is used in patients with cystic echinococcosis:1. when surgical intervention is not feasible .2. as a co-adjunct to surgical treatment. 3. prior to surgical intervention. 4. if preoperative treatment was too short, if spillage has occurred or if viable cysts were found at surgery. 5. following percutaneous drainage of cysts for diagnostic or therapeutic reasons. * alveolar echinococcosis (caused by echinococcus multilocularis)although its efficacy has not been completely demonstrated in clinical trials, albendazole is used in patients with alveolar echinococcosis in the following situations:1. in inoperable disease, particularly in cases of local or distant metastasis.2. following palliative surgery.3. following radical surgery or liver transplantation.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - albendazole, quantity: 400 mg - tablet, chewable - excipient ingredients: povidone; sodium lauryl sulfate; saccharin sodium; lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; maize starch; sunset yellow fcf aluminium lake; flavour - hydatid disease: albendazole is indicated for the treatment of hydatid cysts caused by e. granulosus in adults and children over 6 years of age, where surgical intervention is not feasible because of anatomic site or the presence of multiple cysts. albendazole shows greatest efficacy in the treatment of liver, lung and peritoneal cysts. experience with bone cysts or those in the heart or central nervous system is limited, but cases of successful treatment with prolonged course of albendazole have been reported. albendazole may also be used as an adjunct to surgical excision of hydatid cysts either: 1) prior to surgical intervention, or 2) post-operatively, if pre-operative treatment was too short (less than two separate 28-day cycles) or if viable cysts are found at surgery. larval taeniasis (neurocysticercosis): albendazole is effective in the treatment of neurocysticercosis (ncc) in courses as short as 7 days. other indications: there is also evidence that albendazole is effective against capillaria philippinensis in courses of 10 days.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - albendazole, quantity: 400 mg - tablet, chewable - excipient ingredients: saccharin sodium; sodium lauryl sulfate; croscarmellose sodium; microcrystalline cellulose; povidone; magnesium stearate; maize starch; lactose monohydrate; sunset yellow fcf aluminium lake; flavour - hydatid disease: albendazole is indicated for the treatment of hydatid cysts caused by e. granulosus in adults and children over 6 years of age, where surgical intervention is not feasible because of anatomic site or the presence of multiple cysts. albendazole shows greatest efficacy in the treatment of liver, lung and peritoneal cysts. experience with bone cysts or those in the heart or central nervous system is limited, but cases of successful treatment with prolonged course of albendazole have been reported. albendazole may also be used as an adjunct to surgical excision of hydatid cysts either: 1) prior to surgical intervention, or 2) post-operatively, if pre-operative treatment was too short (less than two separate 28-day cycles) or if viable cysts are found at surgery. larval taeniasis (neurocysticercosis): albendazole is effective in the treatment of neurocysticercosis (ncc) in courses as short as 7 days. other indications: there is also evidence that albendazole is effective against capillaria philippinensis in courses of 10 days.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

wsd agribusiness pty ltd - albendazole - oral solution/suspension - albendazole carbamate-benzimidazole active 112.5 g/l - parasiticides - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - barber's pole worm - haemonchus placei | black scour worm - trichostrongylus spp. | hookworm - bunostomum phlebotomum | intestinal threadworm-strongyloides spp. | liver fluke | lungworm - dictyocaulus viviparus | nodule worm - oesophagostomum radiatum | small brown stomach worm - o. ostertagi | small intestinal worm - cooperia spp. | stomach hair worm | tapeworm - moniezia spp. | hair worm | including inhibited stages | intestinal hair worm | large lungworm | small hair worm | tapeworm - heads/segments

United States - English - NLM (National Library of Medicine)

lineage therapeutics inc - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole is indicated for the treatment of the following infections: neurocysticercosis: albendazole is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts. hydatid disease: albendazole is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . this indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80 to 90% of patients given albendazole for 3 cycles of therapy of 28 days each (see dosage and administration

United States - English - NLM (National Library of Medicine)

edenbridge pharmaceuticals llc. - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albendazole tablets are indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albendazole tablets are contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole tablets. risk summary based on findings from animal reproduction studies, albendazole tablets may cause fetal harm when administered to a pregnant woman. however, available human data from a small number of published case series and reports on the use of multiple-dose albendazole in the 1st trimester of pregnancy, and several published studies on single-dose albendazole use later in pregnancy, have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outc

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albendazole tablets are indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albendazole is contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole. risk summary based on findings from animal reproduction studies, albendazole may cause fetal harm when administered to a pregnant woman. however, available human data from a small number of published case series and reports on the use of multiple-dose albendazole in the 1st trimester of pregnancy, and several published studies on single-dose albendazole use later in pregnancy, have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduct

United States - English - NLM (National Library of Medicine)

golden state medical supply - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albendazole tablets are indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albendazole tablets are contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole tablets. risk summary based on findings from animal reproduction studies, albendazole tablets may cause fetal harm when administered to a pregnant woman. however, available human data from a small number of published case series and reports on the use of multiple-dose albendazole in the 1 st trimester of pregnancy, and several published studies on single-dose albendazole use later in pregnancy, have not identified any drug-associated risks for major birth defects, m

United States - English - NLM (National Library of Medicine)

msn laboratories private limited - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albendazole tablets are indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albendazole is contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole. risk summary based on findings from animal reproduction studies, albendazole may cause fetal harm when administered to a pregnant woman. however, available human data from a small number of published case series and reports on the use of multiple-dose albendazole in the 1st trimester of pregnancy, and several published studies on single-dose albendazole use later in pregnancy, have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reprod

United States - English - NLM (National Library of Medicine)

novadoz pharmaceuticals llc - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albendazole tablets are indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albendazole is contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole. risk summary based on findings from animal reproduction studies, albendazole may cause fetal harm when administered to a pregnant woman. however, available human data from a small number of published case series and reports on the use of multiple-dose albendazole in the 1st trimester of pregnancy, and several published studies on single-dose albendazole use later in pregnancy, have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reprod